Hypoxia-inducible FTL (ferritin light chain), one of the hub ferroptosis regulators (Yan et al., 2023), functions as a new biomarker for the responsiveness to temozolomide in glioblastoma, as well as a prognostic marker (Liu et al., 2020a). This evidence concerns the gene FTL and glioblastoma.